The effectiveness of a low molecular weight heparinoid in chronic intermittent haemodialysis.
A new low molecular weight heparinoid, Org 10172 was compared to heparin in a randomized single blind cross-over study in 55 patients with end-stage renal failure undergoing chronic intermittent haemodialysis. The heparinoid administered as a single pre-dialysis i.v. injection of 34.4 anti-Xa units/kg body weight was compared to standard heparin (loading dose 2,500 IU + continuous infusion of 1,800 IU/hr). Mean anti-Xa plasma levels reached were 0.55 and 0.94 anti-Xa units/ml midway dialysis respectively. All 110 dialysis procedures were successfully performed without clotting or bleeding complications. Analysis of the number of clotted hollow-fibres within the dialysers showed a slight statistically calculated advantage in favour of heparin. Clinically no difference was detected. In conclusion, the heparinoid seems to be a good alternative means of anticoagulation in haemodialysis. As it is administered as a single i.v. predialysis injection it will simplify the dialysis procedure.
Henny
C P
CP
ten Cate
H
H
Surachno
S
S
Stevens
P
P
Büller
H R
HR
den Hartog
M
M
ten Cate
J W
JW
D000328:Adult; D000368:Aged; D000906:Antibodies / Q000032:analysis; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D005170:Factor X / Q000276:immunology; D015951:Factor Xa; D006025:Glycosaminoglycans / Q000008:administration & dosage*; D006493:Heparin / Q000008:administration & dosage; D006496:Heparinoids / Q000008:administration & dosage*; D006497:Heparan Sulfate; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008875:Middle Aged; D008970:Molecular Weight; D006435:Renal Dialysis / Q000379:methods; D013997:Time Factors
D000906:Antibodies; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D005170:Factor X; D015951:Factor Xa; D006025:Glycosaminoglycans; D006493:Heparin; D006496:Heparinoids; D006497:Heparan Sulfate; C035838:danaparoid